These findings reveal a new mechanism by which the dysregulated C5a-C5aR1 axis contributes to tumour cell survival in the hypoxic TME and provide insights into the most effective pharmacological targeting of the C5a-C5aR1 axis. The gene discussed is C5; the disease is neoplasm.